In vivo transmigrated monocytes from patients with stable coronary artery disease have a reduced expression of CD11b.
Coronary artery disease (CAD) is characterized by infiltration of monocyte derived cells in the intima of the vessel wall. We hypothesized that accumulation of these cells is caused partly by an altered monocyte transmigration process in CAD. To gain insight into this issue we applied the skin blister method that allows collection of in vivo transmigrated cells at sites of local inflammation. Nineteen patients with stable CAD and 19 matched controls were enrolled. Markers of inflammation and gradients of chemokines, as well as adhesion molecule expression and up-regulation capacity, were studied. The expression of inflammatory markers, such as C-reactive protein, interleukin (IL)-6, tumour necrosis factor-alpha and IL-10, was similar in patients and controls, indicating that patients were in a stable phase of the disease. Expression of adhesion molecules, CD11b and very late activation antigen-4, on peripheral monocytes did not differ between patients and controls. However, following in vivo transmigration, monocytes in patients with CAD had a significantly reduced expression and mobilization of CD11b. The effect on CD11b could not be reproduced by in vitro stimulation with blister fluid, representing a local inflammatory milieu, or in an in vitro system of transmigration. These findings point towards differences in monocyte CD11b expression and availability at an inflammatory site between patients with CAD and healthy controls.
Paulsson
J M
JM
Department of Clinical Immunology, Karolinska University Hospital, Stockholm, Sweden.
Dadfar
E
E
Held
C
C
Jacobson
S H
SH
Lundahl
J
J
D000368:Aged; D050197:Atherosclerosis / Q000276:immunology; D015415:Biomarkers / Q000032:analysis; D001768:Blister / Q000276:immunology; D039481:CD11b Antigen / Q000276:immunology*; D016022:Case-Control Studies; D002465:Cell Movement; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000276:immunology*; D018450:Disease Progression; D005260:Female; D015870:Gene Expression; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007114:Immunization; D039041:Integrin alpha4beta1 / Q000032:analysis; D016753:Interleukin-10 / Q000032:analysis; D015850:Interleukin-6 / Q000032:analysis; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D015415:Biomarkers; D039481:CD11b Antigen; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D039041:Integrin alpha4beta1; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10